Your search returned 2 results.

Results
	1.	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. [electronic resource] by Gianni, Luca Lladó, Anna Bianchi, Giulia Cortes, Javier Kellokumpu-Lehtinen, Pirkko-Liisa Cameron, David A Miles, David Salvagni, Stefania Wardley, Andrew Goeminne, Jean-Charles Hersberger, Veronica Baselga, José Producer: 20100325 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. [electronic resource] by Wardley, Andrew M Pivot, Xavier Morales-Vasquez, Flavia Zetina, Luis M de Fátima Dias Gaui, Maria Reyes, Douglas Otero Jassem, Jacek Barton, Claire Button, Peter Hersberger, Veronica Torres, Antonio Antón Producer: 20100323 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search